Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 62 for:    Baricitinib

A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01870388
Recruitment Status : Completed
First Posted : June 6, 2013
Results First Posted : April 21, 2017
Last Update Posted : June 6, 2017
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The main purpose of this study is to measure how much of the study drug called baricitinib gets into the blood stream and how long it takes the body to get rid of it. Healthy participants and those with liver disease may enroll. The study will last about 7 days for each participant, not including screening.

Condition or disease Intervention/treatment Phase
Liver Diseases Hepatic Insufficiency Drug: Baricitinib Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Pharmacokinetic Study of Baricitinib in Subjects With Hepatic Dysfunction
Study Start Date : June 2013
Actual Primary Completion Date : July 2013
Actual Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Diseases

Arm Intervention/treatment
Experimental: Baricitinib (Healthy)
Group 1: 4 milligrams (mg) baricitinib administered once, orally, to participants with normal hepatic function.
Drug: Baricitinib
Administered orally
Other Name: LY3009104

Experimental: Baricitinib (Moderate)
Group 2: 4 mg baricitinib administered once, orally, to participants with moderate hepatic impairment.
Drug: Baricitinib
Administered orally
Other Name: LY3009104

Experimental: Baricitinib (Mild)
Group 3: 4 mg baricitinib administered once, orally, to participants with mild hepatic impairment. Enrollment is contingent on data from Groups 1 and 2.
Drug: Baricitinib
Administered orally
Other Name: LY3009104




Primary Outcome Measures :
  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib (LY3009104) [ Time Frame: Predose up to 48 hours (h) postdose ]
  2. PK: Area Under the Concentration Versus Time Curve From Zero to Infinity [AUC(0-∞)] of Baricitinib [ Time Frame: Predose up to 48 h postdose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria for ALL Participants:

  • Male participants agree to use 2 reliable methods of birth control with female partners of child-bearing potential during the study and for at least 3 months following the last dose of study drug
  • Women not of child-bearing potential due to surgical sterilization (at least 6 weeks after surgical bilateral oophorectomy with or without hysterectomy or at least 6 weeks after confirmed tubal occlusion/tubal ligation) confirmed by medical history or menopause
  • Menopausal women with spontaneous amenorrhea for at least 12 months, not induced by a medical condition and by medications and have a follicle-stimulating hormone (FSH) level greater than 40 milli-international units per milliliter (mIU/mL) (unless the participant is taking hormone replacement therapy [HRT])
  • Have a body mass index of 18.5 to 40.0 kilograms per square meter (kg/m^2) inclusive at the time of screening

Additional Inclusion Criteria for Healthy Participants:

  • Are overtly healthy participants, have normal hepatic function and have stable chronic medical conditions
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator

Additional Inclusion Criteria for Hepatically Impaired Participants:

  • Participants with hepatic impairment classified as Child-Pugh score A or B (mild [Group 3, if enrolled] or moderate [Group 2] impairment, respectively). Must have a diagnosis of chronic hepatic impairment (greater than 6 months), with no clinically significant changes within 90 days prior to study drug administration (Day 1). Participants may have mild stable baseline medical conditions for which neither the condition nor treatments received would negatively impact the health of the participant or study conduct
  • Clinical laboratory test results with deviations that are judged by the investigator to be compatible with the hepatic impairment of the participant, or of no additional clinical significance for this study

Exclusion Criteria for ALL Participants:

  • Have received, within the last 30 days, an investigational product as part of a clinical trial, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Persons who have previously completed or withdrawn from study investigating baricitinib, and have previously received the investigational product
  • Women with a positive pregnancy test or who are lactating
  • Have a current or recent history (less than 30 days prior to screening and/or less than 45 days prior to admission to the clinical research unit) of a clinically significant bacterial, fungal, parasitic, viral (excluding rhinopharyngitis), or mycobacterial infection
  • Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior to the first dose
  • Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
  • Have been exposed to a live vaccine within 12 weeks prior to the first dose or expected to need/receive a live vaccine (including herpes zoster vaccination) during the course of the study

Additional Exclusion Criteria for Healthy Participants:

  • Show evidence of acute or chronic liver disease
  • Show evidence of hepatitis B and/or positive hepatitis B and/or positive hepatitis B surface antigen
  • Show evidence of hepatitis C and/or positive hepatitis C antibody
  • Intend to use over-the-counter or prescription medication and/or herbal supplements within 14 days prior to dosing and during the study

Additional Exclusion Criteria for Liver Impaired Participants:

  • Have creatinine clearance less than or equal to 50 milliliter per minute (mL/min) using the Cockcroft and Gault formula
  • Show evidence of spontaneous bacterial peritonitis within 6 month of dosing
  • Have had variceal bleeding within 3 months of check in
  • Show evidence of severe hyponatremia (sodium less than 120 millimolar per liter (mmol/L)
  • Have severe encephalopathy (Grade 3 to 4)
  • Have moderate to severe ascites (moderately hepatically impaired participants only)
  • Show presence of a portal shunt
  • Have hemoglobin less than 9.0 grams per deciliter (g/dL)
  • Have serum bilirubin greater than 15 milligrams per deciliter (mg/dL)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01870388


Locations
Layout table for location information
United States, Florida
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Miami, Florida, United States, 33014
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Orlando, Florida, United States, 32806
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01870388     History of Changes
Other Study ID Numbers: 14600
I4V-MC-JAGC ( Other Identifier: Eli Lilly and Company )
First Posted: June 6, 2013    Key Record Dates
Results First Posted: April 21, 2017
Last Update Posted: June 6, 2017
Last Verified: May 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Hepatic Insufficiency
Liver Failure
Digestive System Diseases